<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Gastrointestinal</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Enterobiotix raises $25.7M for phase IIb of microbiome pill in IBS</title>
      <description>
        <![CDATA[Microbiome specialist Enterobiotix Ltd. has raised £19 million (US$25.7 million) to fund phase IIb development of its lead program EBX-102-02 in the treatment of irritable bowel syndrome with constipation (IBS-C).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730688</guid>
      <pubDate>Wed, 29 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730688-enterobiotix-raises-257m-for-phase-iib-of-microbiome-pill-in-ibs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Glass-pound-symbol1.webp?t=1637697971" type="image/png" medium="image" fileSize="286512">
        <media:title type="plain">British pound symbol</media:title>
      </media:content>
    </item>
    <item>
      <title>Montai’s MTAI-1025 demonstrates efficacy in ulcerative colitis</title>
      <description>
        <![CDATA[The combination of impaired epithelial barrier function, mucosal inflammation and elevated oxidative stress is determinant for the pathogenesis of ulcerative colitis (UC). NF-E2-related factor 2 (NRF2) is an important transcription factor for modulating antioxidant defenses, inhibiting inflammatory pathways and regenerating the epithelial barrier. Montai Therapeutics Inc. has developed a potent and selective NRF2 agonist compound, MTAI-1025, for the management of UC using its proprietary CONECTA platform.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730743</guid>
      <pubDate>Wed, 29 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730743-montais-mtai-1025-demonstrates-efficacy-in-ulcerative-colitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/IBD-inflammatory-bowel-disease-Crohns-Colitis.webp?t=1745258495" type="image/jpeg" medium="image" fileSize="193405">
        <media:title type="plain">Illustration of intestines with inflammation</media:title>
      </media:content>
    </item>
    <item>
      <title>Novel method BOOSTs organ growth after transplantation</title>
      <description>
        <![CDATA[A major challenge in tissue engineering is not only achieving the correct cellular organization of an engineered tissue, but also expanding it to a clinically useful size after implantation. Researchers from the Wyss Institute at Harvard University have developed a synthetic biology platform that genetically programs tissues to grow large organ implants on demand. Building on a 2017 study suggesting engineered liver tissues could respond to regenerative signals released after injury, the researchers set out to identify and harness those cues.
<br><br>
  “If we could figure out what those signals were, we could synthetically drive these factors locally in an implant to control its growth ourselves,” first author Amy Stoddard told <em>BioWorld</em>. Stoddard is a postdoctoral researcher at the Wyss Institute.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730717</guid>
      <pubDate>Tue, 28 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730717-novel-method-boosts-organ-growth-after-transplantation</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Neon-arrows.webp?t=1777389173" type="image/jpeg" medium="image" fileSize="548927">
        <media:title type="plain">Pink and blue neon arrows demonstrating acceleration</media:title>
      </media:content>
    </item>
    <item>
      <title>Elpiscience’s bispecific antibody ES-302 reduces disease activity in IBD model</title>
      <description>
        <![CDATA[Researchers from Elpiscience Biopharmaceuticals Inc. hypothesized that dual targeting of the TL1A/DR3 and IL-23 signaling pathways with a single bispecific antibody would exert superior efficacy by reshaping the immune landscape in disorders such as inflammatory bowel disease (IBD). The company has developed a bispecific antibody targeting both TL1A/DR3 and IL-23p19 – ES-302 – for the treatment of IBD.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730557</guid>
      <pubDate>Wed, 22 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730557-elpisciences-bispecific-antibody-es-302-reduces-disease-activity-in-ibd-model</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Gastrointestinal-vector-framework.webp?t=1739806991" type="image/jpeg" medium="image" fileSize="232822">
        <media:title type="plain">Illustration of intestinal track</media:title>
      </media:content>
    </item>
    <item>
      <title>Daiichi to divest consumer health unit to Suntory for $1.5B</title>
      <description>
        <![CDATA[Daiichi Sankyo. Co. Ltd. will begin a phased sale of its consumer health subsidiary, Daiichi Sankyo Healthcare Co. Ltd., to Suntory Holdings Ltd., as the Tokyo-based drugmaker sharpens its focus on oncology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730574</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730574-daiichi-to-divest-consumer-health-unit-to-suntory-for-15b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Arrows-opposite-directions.webp?t=1588276411" type="image/png" medium="image" fileSize="20890">
        <media:title type="plain">Two arrows in opposite directions</media:title>
      </media:content>
    </item>
    <item>
      <title>Daiichi to divest consumer health unit to Suntory for $1.5B</title>
      <description>
        <![CDATA[Daiichi Sankyo. Co. Ltd. will begin a phased sale of its consumer health subsidiary, Daiichi Sankyo Healthcare Co. Ltd., to Suntory Holdings Ltd., as the Tokyo-based drugmaker sharpens its focus on oncology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730407</guid>
      <pubDate>Fri, 17 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730407-daiichi-to-divest-consumer-health-unit-to-suntory-for-15b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Arrows-opposite-directions.webp?t=1588276411" type="image/png" medium="image" fileSize="20890">
        <media:title type="plain">Two arrows in opposite directions</media:title>
      </media:content>
    </item>
    <item>
      <title>Mayinglong Pharmaceutical presents new 5-HT4 receptor agonists</title>
      <description>
        <![CDATA[Mayinglong Pharmaceutical Group Co. Ltd. has reported new 5-HT4 receptor agonists that are potentially useful for the treatment of gastroesophageal reflux disease, constipation, irritable bowel syndrome, dyspepsia, delayed gastric emptying (gastroparesis), intestinal pseudo-obstruction, diabetic gastroparesis and postoperative Ileus.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730360</guid>
      <pubDate>Tue, 14 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730360-mayinglong-pharmaceutical-presents-new-5-ht4-receptor-agonists</link>
    </item>
    <item>
      <title>Hubei Bio-Pharmaceutical Industrial Technological Institute divulges new VAV1 degraders</title>
      <description>
        <![CDATA[Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. has identified new molecular glue degrader compounds acting as proto-oncogene Vav (VAV1)/protein cereblon (CRBN) interaction inducers for degradation of VAV1 reported to be useful for the treatment of inflammatory bowel disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730359</guid>
      <pubDate>Tue, 14 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730359-hubei-bio-pharmaceutical-industrial-technological-institute-divulges-new-vav1-degraders</link>
    </item>
    <item>
      <title>Spyre’s SPY-001 induces better outcomes in ulcerative colitis</title>
      <description>
        <![CDATA[Spyre Therapeutics Inc. is off to a good start in its goal to create the best combination therapy for inflammatory bowel disease, a group of chronic, relapsing autoimmune conditions of the digestive tract that encompasses Crohn’s disease and ulcerative colitis. The Waltham, Mass.-based company estimates the market for IBD is currently at approximately $25 billion but will jump to around $40 billion in 2030.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730280</guid>
      <pubDate>Mon, 13 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730280-spyres-spy-001-induces-better-outcomes-in-ulcerative-colitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Ulcerative-colitis-illustration.webp?t=1776115680" type="image/jpeg" medium="image" fileSize="312045">
        <media:title type="plain">Ulcerative colitis</media:title>
      </media:content>
    </item>
    <item>
      <title>GLP-1R drug response tied to variants in target genes</title>
      <description>
        <![CDATA[The development of glucagon-like peptide 1 receptor (GLP-1R) agonists, such as semaglutide and tirzepatide, has been a game changer in the clinical management of overweight and obesity, but there is interpersonal variability in efficacy of these medications for weight loss, as well as in the incidence of undesired side effects. Investigators from the 23andMe Research Institute have shed some light on how variations in the GLP-1R and GIP receptor (GIPR) genes impact their effectiveness and the occurrence of side effects.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730325</guid>
      <pubDate>Mon, 13 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730325-glp-1r-drug-response-tied-to-variants-in-target-genes</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Omics-genetics-DNA-human-body-illustration.webp?t=1776093243" type="image/jpeg" medium="image" fileSize="864177">
        <media:title type="plain">Illustration of the human body next to a DNA double helix</media:title>
      </media:content>
    </item>
    <item>
      <title>TIPE2 silencing attenuates colitis</title>
      <description>
        <![CDATA[The tumor necrosis factor (TNF)-α-induced protein 8-like 2 (TIPE2), predominantly expressed in bone marrow-derived cells or lymphoid tissues, is an essential regulator of immune homeostasis. TIPE2 acts as a key negative modulator of inflammatory signaling through the suppression of toll-like receptor (TLR) activity, with TIPE2-deficient mice exhibiting spontaneous systemic inflammation and premature death.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730262</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730262-tipe2-silencing-attenuates-colitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Gastrointestinal-system-illustration.webp?t=1769098607" type="image/jpeg" medium="image" fileSize="679694">
        <media:title type="plain">Gastrointestinal system</media:title>
      </media:content>
    </item>
    <item>
      <title>Proqr Therapeutics expands early-stage pipeline</title>
      <description>
        <![CDATA[Proqr Therapeutics NV has highlighted the continued progression and expansion of its early-stage pipeline of RNA editing therapies, including programs in cholestatic diseases, Hurler syndrome, metabolic dysfunction-associated steatohepatitis and Rett syndrome.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730238</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730238-proqr-therapeutics-expands-early-stage-pipeline</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/RNA-strand.webp?t=1609964773" type="image/png" medium="image" fileSize="440899">
        <media:title type="plain">RNA strand</media:title>
      </media:content>
    </item>
    <item>
      <title>Korea roundup: Alteogen, Celltrion lead biotech deals</title>
      <description>
        <![CDATA[Subcutaneous formulation technology, microbiomes and oncological assets drove dealmaking in South Korea’s biotech sector this week.&nbsp;]]>
      </description>
      <guid>http://www.bioworld.com/articles/730087</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730087-korea-roundup-alteogen-celltrion-lead-biotech-deals</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Celltrion-Kobiolabs-3-26.webp?t=1774632497" type="image/jpeg" medium="image" fileSize="738862">
        <media:title type="plain">Seo Jin-seok of Celltrion (right) with Ko Kwang-pyo of Kobiolabs (left)</media:title>
        <media:description type="plain">Seo Jin-seok, CEO, Celltrion (right) with Ko Kwang-pyo, founder and CEO, Kobiolabs (left).</media:description>
      </media:content>
    </item>
    <item>
      <title>US FDA says no, again, to Vanda’s tradipitant in gastroparesis</title>
      <description>
        <![CDATA[The U.S. path forward is narrowing for Vanda Pharmaceuticals Inc.’s tradipitant as a treatment for gastroparesis, a serious disorder for which there’s been no new treatment in several decades.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729966</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729966-us-fda-says-no-again-to-vandas-tradipitant-in-gastroparesis</link>
    </item>
    <item>
      <title>HHEX emerges as a potential IBD target</title>
      <description>
        <![CDATA[In recent work, researchers from Shanghai Jiaotong University School of Medicine and Shanghai Colorectal Cancer Research Center reported that the transcription factor hematopoietically expressed homeobox (HHEX) promotes tumorigenesis in colitis-associated colorectal cancer. In a new paper, the team aimed to further characterize the biological function and potentially dysregulated mechanisms of HHEX during intestinal inflammation, which remained largely unexplored.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730001</guid>
      <pubDate>Fri, 27 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730001-hhex-emerges-as-a-potential-ibd-target</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Gastrointestinal-IBD-Crohns.webp?t=1730736512" type="image/jpeg" medium="image" fileSize="256580">
        <media:title type="plain">Illustration for inflammatory bowel disease</media:title>
      </media:content>
    </item>
    <item>
      <title>Korea roundup: Alteogen, Celltrion lead biotech deals</title>
      <description>
        <![CDATA[Subcutaneous (SC) formulation technology, microbiomes and oncological assets drove dealmaking in South Korea’s biotech sector this week.&nbsp;]]>
      </description>
      <guid>http://www.bioworld.com/articles/729906</guid>
      <pubDate>Thu, 26 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729906-korea-roundup-alteogen-celltrion-lead-biotech-deals</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Celltrion-Kobiolabs-3-26.webp?t=1774632497" type="image/jpeg" medium="image" fileSize="738862">
        <media:title type="plain">Seo Jin-seok of Celltrion (right) with Ko Kwang-pyo of Kobiolabs (left)</media:title>
        <media:description type="plain">Seo Jin-seok, CEO, Celltrion (right) with Ko Kwang-pyo, founder and CEO, Kobiolabs (left).</media:description>
      </media:content>
    </item>
    <item>
      <title>GSK’s IBAT inhibitor wins US FDA nod for cholestatic pruritus </title>
      <description>
        <![CDATA[With the U.S. FDA’s approval of GSK plc’s ileal bile acid transporter (IBAT) inhibitor, Lynavoy (linerixibat), patients with primary biliary cholangitis no longer need off-label treatments for a debilitating internal itch symptom called cholestatic pruritus.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729745</guid>
      <pubDate>Thu, 19 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729745-gsks-ibat-inhibitor-wins-us-fda-nod-for-cholestatic-pruritus</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Wood-approved-stamp-red.webp?t=1670969940" type="image/png" medium="image" fileSize="323015">
        <media:title type="plain">Red wooden approved stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>R1’s $77.5M series A to fund CKD trial of oral phosphate inhibitor</title>
      <description>
        <![CDATA[Newco R1 Therapeutics Inc. has launched with an oversubscribed $77.5 million series A, providing the means to take AP-306, a potentially first-in-class hyperphosphatemia therapy through phase IIb development in patients with chronic kidney disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729551</guid>
      <pubDate>Tue, 17 Mar 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729551-r1s-775m-series-a-to-fund-ckd-trial-of-oral-phosphate-inhibitor</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Nephrology/kidney-nephrology.webp?t=1589217921" type="image/png" medium="image" fileSize="520589">
        <media:title type="plain">Kidneys</media:title>
      </media:content>
    </item>
    <item>
      <title>KIST and Neocannbio report new NO production inhibitors</title>
      <description>
        <![CDATA[The Korea Institute of Science and Technology (KIST) and Neocannbio Co. Ltd. have jointly identified compounds acting as nitric oxide (NO) production inhibitors with potential for the treatment of inflammatory bowel disease (IBD).]]>
      </description>
      <guid>http://www.bioworld.com/articles/729334</guid>
      <pubDate>Wed, 04 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729334-kist-and-neocannbio-report-new-no-production-inhibitors</link>
    </item>
    <item>
      <title>Jiuyuan seeks approval of Wegovy biosimilar in China</title>
      <description>
        <![CDATA[China’s National Medical Products Administration has accepted for review Jiuyuan Genetic Biopharmaceutical Co. Ltd.’s drug application for Jikeqin, a biosimilar product to Novo Nordisk A/S’s Wegovy (semaglutide) for obesity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729318</guid>
      <pubDate>Tue, 03 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729318-jiuyuan-seeks-approval-of-wegovy-biosimilar-in-china</link>
    </item>
    <item>
      <title>GPR68 negative allosteric modulator ameliorates ulcerative colitis</title>
      <description>
        <![CDATA[G-protein coupled receptor 68 (GPR68) is an acid-sensing protein receptor that has been implicated in inflammatory bowel disease (IBD) pathogenesis by its modulation of the inflammatory response and fibrosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729119</guid>
      <pubDate>Fri, 27 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729119-gpr68-negative-allosteric-modulator-ameliorates-ulcerative-colitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Gastrointestinal-vector-framework.webp?t=1739806991" type="image/jpeg" medium="image" fileSize="232822">
        <media:title type="plain">Illustration of intestinal track</media:title>
      </media:content>
    </item>
    <item>
      <title>SIK2 inhibitor mitigates pathology in ulcerative colitis models </title>
      <description>
        <![CDATA[Salt-inducible kinase 2 (SIK2) is a serine/threonine kinase that regulates transcriptional programs in myeloid cells by phosphorylating transcriptional coregulators. In macrophages, SIK2 promotes the expression of proinflammatory cytokines and contributes to the balance between inflammatory and regulatory responses. Researchers from Nimbus Therapeutics LLC presented the preclinical efficacy of NTX-147, a SIK2 selective inhibitor, in ex vivo models of ulcerative colitis (UC).]]>
      </description>
      <guid>http://www.bioworld.com/articles/729114</guid>
      <pubDate>Fri, 27 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729114-sik2-inhibitor-mitigates-pathology-in-ulcerative-colitis-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/3D-illustration-of-human-digestive-system.webp?t=1709246262" type="image/jpeg" medium="image" fileSize="171684">
        <media:title type="plain">3D illustration of human digestive system</media:title>
      </media:content>
    </item>
    <item>
      <title>Jiuyuan seeks approval of Wegovy biosimilar in China</title>
      <description>
        <![CDATA[China’s National Medical Products Administration has accepted for review Jiuyuan Genetic Biopharmaceutical Co. Ltd.’s drug application for Jikeqin, a biosimilar product to Novo Nordisk A/S’s Wegovy (semaglutide) for obesity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729245</guid>
      <pubDate>Thu, 26 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729245-jiuyuan-seeks-approval-of-wegovy-biosimilar-in-china</link>
    </item>
    <item>
      <title>Targeting OGFOD1 improves hepatic ischemia-reperfusion injury</title>
      <description>
        <![CDATA[Hepatic ischemia-reperfusion injury (HIRI) is a severe pathologic condition associated with poor outcomes when individuals suffer from hemorrhagic shock, liver resection or transplantation surgery, leading to severe liver impairment and sometimes dysfunction in other organs. Chinese researchers have explored the potential of prolyl 3-hydroxylase OGFOD1 as a target for HIRI management, since it has been reported as a crucial regulator of gene expression, especially for translation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729058</guid>
      <pubDate>Thu, 26 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729058-targeting-ogfod1-improves-hepatic-ischemia-reperfusion-injury</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-illustration.webp?t=1613674462" type="image/png" medium="image" fileSize="432664">
        <media:title type="plain">Liver illustration</media:title>
        <media:description type="plain">Credit: Georgia State University</media:description>
      </media:content>
    </item>
    <item>
      <title>Vivtex’s oral drug delivery approach draws Novo in $2.1B deal</title>
      <description>
        <![CDATA[Coming off a U.S. FDA approval of the first GLP-1 in pill format, Novo Nordisk A/S leaned further into oral drug delivery efforts, partnering with Vivtex Corp. to develop next-generation oral formulations of peptide and protein therapeutics in a potential $2.1 billion deal that marks the highest-profile news for Vivtex since the firm spun out of MIT in 2018.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729200</guid>
      <pubDate>Wed, 25 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729200-vivtexs-oral-drug-delivery-approach-draws-novo-in-21b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/GI-ORIS-pic-Vivtex-2-25.webp?t=1772058346" type="image/jpeg" medium="image" fileSize="528373">
        <media:title type="plain">GI-ORIS-pic-Vivtex-2-25.jpg</media:title>
        <media:description type="plain">GI-ORIS, or “GI tract on a chip” screening system.
Credit: Vivtex Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Spyre reports enhanced efficacy of anti-TL1A and anti-IL-23 combination </title>
      <description>
        <![CDATA[Researchers from Spyre Therapeutics Inc. reported on the therapeutic efficacy of combining anti-TL1A and anti-IL-23 antibodies in preclinical models of colitis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729037</guid>
      <pubDate>Wed, 25 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729037-spyre-reports-enhanced-efficacy-of-anti-tl1a-and-anti-il-23-combination</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/IBD-ulcerative-colitis.webp?t=1668182386" type="image/png" medium="image" fileSize="1246429">
        <media:title type="plain">Gastrointestinal system with ulcerative colitis.</media:title>
      </media:content>
    </item>
    <item>
      <title>GS-8670 restores epithelial barrier function in IBD models </title>
      <description>
        <![CDATA[The farnesoid X receptor (FXR) is a nuclear receptor that plays a central role in bile acid regulation, intestinal barrier integrity, immune modulation and microbiome balance, all key factors involved in the development of inflammatory bowel disease (IBD). Researchers from Gilead Sciences Inc. reported the effects of GS-8670, an FXR agonist, in models of colitis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729035</guid>
      <pubDate>Wed, 25 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729035-gs-8670-restores-epithelial-barrier-function-in-ibd-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/IBD-inflammatory-bowel-disease-Crohns-Colitis.webp?t=1745258495" type="image/jpeg" medium="image" fileSize="193405">
        <media:title type="plain">Illustration of intestines with inflammation</media:title>
      </media:content>
    </item>
    <item>
      <title>Ailux characterizes ALX-001 for IMIDs</title>
      <description>
        <![CDATA[Researchers from Shanghai Ailux Biotechnology Co. Ltd. have disclosed preclinical data regarding their humanized bispecific antibody ALX-001 targeting TL1A and IL-23 for the potential treatment of immune-mediated inflammatory diseases (IMIDs).]]>
      </description>
      <guid>http://www.bioworld.com/articles/729018</guid>
      <pubDate>Tue, 24 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729018-ailux-characterizes-alx-001-for-imids</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Macrophage-releasing-cytokines-illustration.webp?t=1771947007" type="image/jpeg" medium="image" fileSize="590737">
        <media:title type="plain">Illustration of macrophage releasing cytokines</media:title>
      </media:content>
    </item>
    <item>
      <title>Novo’s next-gen obesity drug fails to beat Lilly's Zepbound</title>
      <description>
        <![CDATA[Shares in Novo Nordisk A/S took another battering after the company announced its next-generation obesity drug Cagrisema failed to show noninferiority to Eli Lilly and Co. Inc.’s Zepbound in an open-label comparator study.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729176</guid>
      <pubDate>Mon, 23 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729176-novos-next-gen-obesity-drug-fails-to-beat-lillys-zepbound</link>
    </item>
    <item>
      <title>Stoked Bio licenses rights to enterololin for Crohn’s disease</title>
      <description>
        <![CDATA[Stoked Bio Inc. has secured an exclusive global license from McMaster University for the patents covering enterololin, a promising narrow-spectrum antibiotic.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728937</guid>
      <pubDate>Thu, 19 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728937-stoked-bio-licenses-rights-to-enterololin-for-crohns-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NIAID-Scanning-electron-micrograph-of-Escherichia-coli.webp?t=1667837128" type="image/png" medium="image" fileSize="2031153">
        <media:title type="plain">Colorized scanning electron micrograph of E. coli bacteria.</media:title>
        <media:description type="plain">Escherichia coli bacteria. Credit: National Institute of Allergy and Infectious Diseases, NIH
</media:description>
      </media:content>
    </item>
  </channel>
</rss>
